Massachusetts General Hospital

Boston, MA

Sorting 14 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

inMMyCAR

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Phase 1
  • Has results

Accepting patients

MagnetisMM-20

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

TRIlogy-3

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
  • Trispecific Antibody
  • BCMA
  • GPRC5D
  • Phase 2

Accepting patients

Elranatamab as Consolidation

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
  • Bispecific T Cell Engager (BiTE)
  • Bispecific Antibody
  • CD3
  • BCMA
  • Phase 2

Accepting patients

ISABELA

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/​Refractory Multiple Myeloma (ISABELA)
  • Monoclonal Antibody
  • CD38
  • Quadruplet Therapy
  • Phase 2

Accepting patients

MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
  • H3K36me2
  • Phase 1
  • Has results

Not yet accepting

mRNA-2808

A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
  • BCMA
  • GPRC5D
  • FCRH5
  • Phase 1/2

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Accepting patients

TriPRIL CAR T

TriPRIL CAR T Cells in Multiple Myeloma
  • CAR T Cell
  • BCMA
  • APRIL
  • Phase 1
1 hidden based on your filters.Show All